Individualized Neoantigen Vaccines: First Pivotal Readouts | Oncology Modality Intelligence

Description

List of Tables

Individualized neoantigen vaccines are oncology's most literal promise: sequence a patient's tumor, find the mutations unique to it, and manufacture a vaccine that teaches the immune system to attack exactly that cancer. The concept has survived a decade of platform iterations, and it now faces its moment of judgment - the first pivotal readouts for the class, led by the Moderna-Merck V940 (intismeran autogene) program paired with pembrolizumab across the INTerpath study series, with the adjuvant-melanoma trial delivering the class's first Phase 3 answer in August 2026. Behind the leaders, the field is differentiated rather than crowded: BioNTech and Roche's autogene cevumeran pursues pancreatic cancer, where even small effects would matter; Gritstone's GRANITE program tests ctDNA-guided vaccination in molecular-relapse colorectal cancer; Transgene and NEC - Japan's flagship entry - use viral vectors with AI-driven antigen selection; and off-the-shelf variants from Nouscom and Nykode probe whether personalization is necessary at all. The contested questions are fundamental. Does the biology deliver in randomized settings, or only in the single-arm studies that built the field's reputation? Can manufacturing turnaround - biopsy to injection in weeks - hold at pivotal scale? And what regulatory framework governs a product that is different for every patient? For Japan the questions are concrete: whether Japanese sites participate in the INTerpath and successor programs, how PMDA will evaluate individualized products whose composition changes per patient, and whether NEC's domestic effort with Transgene can anchor Japanese capability in the class. This report maps the platform science, the pivotal programs and their designs, the manufacturing and logistics chain, the regulatory frameworks in the US, EU, and Japan, the Japan-participation question flagged where unverified, and the commercial model for a therapy manufactured one patient at a time. It serves oncology investors, vaccine-platform business-development teams, CROs and manufacturers, and Japanese stakeholders deciding how much of this future to build at home.

Scope and Coverage

The report covers neoantigen biology and platform design, the V940/INTerpath and BNT122 programs, viral-vector and off-the-shelf alternatives, individualized manufacturing logistics, regulatory frameworks including PMDA considerations, and Japan's position from NEC's program to trial participation.

Report Highlights

V940 (intismeran autogene) and the INTerpath program: designs, indications, and the first Phase 3 readout (2026)
Autogene cevumeran (BNT122) and the adjuvant pancreatic strategy with Roche
Gritstone GRANITE and the ctDNA-guided vaccination concept in colorectal cancer
NEC and Transgene TG4050: Japan's flagship individualized-vaccine effort
PMDA's framework for individualized products: precedent and open questions
Manufacturing turnaround, logistics, and the commercial model for one-patient products

Product Code: JPH-107

Table of Content

1. Executive Summary

2. Individualized Neoantigen Vaccines: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

Moderna (US) - intismeran autogene (V940/mRNA-4157); INTerpath-001 delivered the class's first Phase 3 readout (Aug 2026)
Merck & Co (US) - co-developer pairing V940 with the pembrolizumab backbone across the INTerpath program
BioNTech (DE) - autogene cevumeran (BNT122, with Roche); adjuvant pancreatic Phase 2; iNeST platform
Roche (CH) - Genentech partner on BNT122; combination strategy with atezolizumab
Gritstone bio (US) - GRANITE ctDNA-guided program in MRD-defined colorectal cancer amid corporate restructuring
Transgene (FR) - TG4050 viral-vector individualized vaccine developed with NEC
NEC (JP) - Japan's flagship individualized neoantigen effort; AI-driven antigen selection with Transgene
Stemirna (CN) - China mRNA company with personalized neoantigen programs
Nouscom (IT) - NOUS-PEV individualized and NOUS-209 off-the-shelf viral-vector vaccines
Nykode (NO) - VB10.NEO individualized vaccine experience on an APC-targeted platform

Product Code: JPH-107

List of Tables

Table 1. Neoantigen biology primer: mutation burden, antigen selection, and immune priming
Table 2. Platform taxonomy: mRNA, viral vector, peptide, and DNA approaches
Table 3. V940/mRNA-4157 (intismeran autogene): design and the Moderna-Merck collaboration structure
Table 4. INTerpath-001: adjuvant melanoma Phase 3 design and the 2026 readout context
Table 5. The broader INTerpath program across NSCLC, bladder, and other indications
Table 6. Pembrolizumab backbone strategy in the V940 program
Table 7. Autogene cevumeran (BNT122): BioNTech iNeST platform design
Table 8. BioNTech-Roche partnership structure for BNT122 with atezolizumab
Table 9. Adjuvant pancreatic cancer development plan for BNT122
Table 10. Gritstone GRANITE program: ctDNA-guided vaccination in MRD-defined colorectal cancer
Table 11. Gritstone corporate restructuring and program-continuity questions
Table 12. Transgene TG4050: viral-vector individualized vaccine design
Table 13. NEC AI-driven antigen selection and the Transgene partnership
Table 14. Nouscom NOUS-PEV and NOUS-209: individualized and off-the-shelf viral-vector programs
Table 15. Nykode VB10.NEO experience on the APC-targeted platform
Table 16. Stemirna personalized neoantigen programs in China
Table 17. Shared-neoantigen and off-the-shelf alternatives to personalization
Table 18. Adjuvant-versus-metastatic development logic for cancer vaccines
Table 19. Combination strategies pairing vaccines with checkpoint inhibitors
Table 20. Antigen-selection algorithm competition: bioinformatics as differentiation
Table 21. Manufacturing workflow from biopsy to bedside for individualized products
Table 22. Turnaround-time engineering and its clinical consequences
Table 23. Quality-release frameworks for patient-specific batches
Table 24. FDA regulatory approach to individualized neoantigen products
Table 25. EU regulatory framework for personalized vaccines under the ATMP umbrella
Table 26. PMDA precedent and open questions for individualized products
Table 27. Japan site participation in INTerpath and successor studies
Table 28. Japanese genomic-medicine infrastructure relevant to neoantigen identification
Table 29. C-CAT and panel-sequencing touchpoints with vaccine workflows
Table 30. Melanoma treatment landscape in Japan and the adjuvant opportunity
Table 31. Pancreatic cancer adjuvant setting in Japan: standards and gaps
Table 32. Colorectal MRD testing in Japan and its convergence with vaccine strategies
Table 33. Logistics-network requirements for individualized products in Japan
Table 34. Commercial-model considerations for one-patient-at-a-time therapies
Table 35. NHI pricing questions for individualized vaccines
Table 36. Deal and partnership activity in neoantigen vaccines, 2023-2026
Table 37. Competitive-position matrix of individualized vaccine platforms
Table 38. Scenario grid for the class after first pivotal readouts
Table 39. Scenario grid for Japan participation and domestic capability
Table 40. Risk register for investors in individualized-vaccine platforms
Table 41. Risk register for combination partners dependent on vaccine programs
Table 42. Key opinion leader landscape in Japanese immuno-oncology relevant to vaccines
Table 43. CRO and manufacturing-capacity map for individualized products
Table 44. Biomarker and MRD infrastructure requirements for vaccine development
Table 45. Watchlist of class readouts and regulatory events, 2026-2028
Table 46. Stakeholder map: platform companies, checkpoint partners, regulators, and manufacturers
Table 47. Technology-assessment framework for antigen-selection platforms
Table 48. Historical lessons from earlier cancer-vaccine generations
Table 49. Implications of the class for Japanese trial and sequencing infrastructure
Table 50. Timeline of individualized neoantigen vaccine development, 2017-2026

List of Figures

Figure 1. Neoantigen identification and vaccine-design workflow
Figure 2. Platform map: mRNA, viral vector, peptide, and DNA
Figure 3. Moderna-Merck collaboration structure for V940
Figure 4. INTerpath-001 design schematic in adjuvant melanoma
Figure 5. INTerpath program map across indications
Figure 6. Checkpoint-backbone strategy for individualized vaccines
Figure 7. BioNTech iNeST platform and autogene cevumeran design
Figure 8. BioNTech-Roche partnership map for BNT122
Figure 9. Adjuvant pancreatic development plan for BNT122
Figure 10. GRANITE ctDNA-guided vaccination concept
Figure 11. Gritstone restructuring and program-continuity map
Figure 12. Transgene TG4050 viral-vector design
Figure 13. NEC antigen-selection AI in the Transgene partnership
Figure 14. Nouscom and Nykode alternative-platform positions
Figure 15. China neoantigen landscape including Stemirna
Figure 16. Off-the-shelf versus individualized strategy map
Figure 17. Adjuvant-versus-metastatic development logic
Figure 18. Vaccine-checkpoint combination architecture
Figure 19. Antigen-selection algorithm competition landscape
Figure 20. Biopsy-to-bedside manufacturing workflow
Figure 21. Turnaround-time engineering map
Figure 22. Release-testing framework for patient-specific batches
Figure 23. FDA pathway for individualized products
Figure 24. EU ATMP framework applied to personalized vaccines
Figure 25. PMDA framework questions for individualized products
Figure 26. Japan site-participation map across pivotal programs
Figure 27. Japanese genomic-medicine infrastructure touchpoints
Figure 28. C-CAT integration with neoantigen workflows
Figure 29. Japanese melanoma adjuvant landscape
Figure 30. Japanese pancreatic adjuvant landscape
Figure 31. Colorectal MRD convergence with vaccine strategies in Japan
Figure 32. Logistics network for individualized products in Japan
Figure 33. Commercial-model schematic for one-patient products
Figure 34. NHI pricing question map for individualized vaccines
Figure 35. Neoantigen deal and partnership map, 2023-2026
Figure 36. Competitive-position matrix of vaccine platforms
Figure 37. Class scenario tree after first pivotal readouts
Figure 38. Japan-participation scenario tree
Figure 39. Risk map for platform investors
Figure 40. Risk map for combination partners
Figure 41. Japanese immuno-oncology KOL landscape for vaccines
Figure 42. CRO and manufacturing capacity map
Figure 43. MRD and biomarker infrastructure requirements
Figure 44. Class readout and regulatory calendar, 2026-2028
Figure 45. Stakeholder map across the individualized-vaccine chain
Figure 46. Antigen-selection technology-assessment framework
Figure 47. Lessons map from earlier cancer-vaccine generations
Figure 48. Implications map for Japanese sequencing and trial infrastructure
Figure 49. Key-question tree for investors and BD teams
Figure 50. Individualized neoantigen vaccine timeline, 2017-2026

Individualized Neoantigen Vaccines: First Pivotal Readouts | Oncology Modality Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Individualized Neoantigen Vaccines: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures